Biopharma · FDA Approvals · Stock

KZIA Kazia Therapeutics

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Ak…

Assets on file: paxalisib

Start live analysis of KZIA Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for KZIA, including recently decided ones.

October 2026

Oct 2026

~ Oct 2026

KZIAKazia Therapeutics

paxalisib: Phase 2 trial NCT03994796 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

December 2026

Dec 2026

Dec 1, 2026

in 39 days

KZIAKazia Therapeutics

paxalisib: Phase 2 trial NCT04906096 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

February 2027

Feb 2027

~ Feb 2027

KZIAKazia Therapeutics

paxalisib: Phase 1/Phase 2 trial NCT07287202 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

December 2027

Dec 2027

Dec 31, 2027

in 434 days

KZIAKazia Therapeutics

paxalisib: Phase 2 trial NCT05009992 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

June 2028

Jun 2028

~ Jun 2028

KZIAKazia Therapeutics

paxalisib: Phase 2/Phase 3 trial NCT03970447 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

January 2029

Jan 2029

Jan 19, 2029

in 819 days

KZIAKazia Therapeutics

paxalisib: Phase 1/Phase 2 trial NCT07391215 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

December 2030

Dec 2030

~ Dec 2030

KZIAKazia Therapeutics

paxalisib: Phase 1/Phase 2 trial NCT06208657 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

December 2035

Dec 2035

Dec 31, 2035

in 3356 days

KZIAKazia Therapeutics

paxalisib: Phase 2 trial NCT07447076 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Recent first-hand events

Every first-hand event for KZIA, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Sep 28, 2026

03:22 PM

KZIAKazia Therapeutics

paxalisib · NCT03994796 registry update

primary_completion: 2026-10 → 2025-11-13

Trial registry changeClinicalTrials.gov

Sep 25, 2026

03:20 PM

KZIAKazia Therapeutics

paxalisib · NCT05183204 registry update

status: SUSPENDED → COMPLETED; primary_completion: 2026-06 → 2026-08-10; completion: 2026-06 → 2026-08-10; enrollment: 33 → 24; why_stopped: Pending results of interim analysis →

Trial registry changeClinicalTrials.gov Open record

Sep 22, 2026

07:30 PM

KZIAKazia Therapeutics

Kazia Therapeutics: Sovargen doses first patient in Phase 1b/2a trial of paxalisib in FCD T2 and TSC

Sovargen has dosed the first patient in its Phase 1b/2a trial of paxalisib (SVG103) for intractable epilepsy in FCD T2 and TSC. This triggers a $2M development milestone payment to Kazia under their 2024 licensing agreement and expands paxalisib development into non-oncology rare seizure disorders.

Trial registry changeCompany press release